Phase II clinical trial of G207 HSV to treat children with high grade gliomas
Ended Project Grant Awarded Last action
- Award ID
- R44CA250883
- Recipient
-
Treovir Inc. UEI P3MKE8JK22Q8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,932,957
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Alabama, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$241,532 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $890,765 | |
| Amendment | $890,765 | |
| Amendment | $890,765 | |
| Amendment | -$0 | |
| Amendment | -$0 | |
| Amendment | -$0 | |
| Amendment | -$0 | |
| Amendment | $1,625 | |
| Amendment | $1,625 | |
| Amendment | $1,625 | |
| Amendment | -$1,625 | |
| Amendment | -$1,625 | |
| Amendment | $1,625 | |
| Amendment | $1,625 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $611,912 | |
| Amendment | -$611,912 | |
| Amendment | -$611,912 | |
| Amendment | $611,912 | |
| Amendment | -$611,912 | |
| Original award | $1,109,232 |
Show all 29
Quick answers
Who received award R44CA250883?
R44CA250883 was awarded to Treovir Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2020.
How much is award R44CA250883 worth?
$2,932,957 has been obligated on R44CA250883.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award